The Vasculitis Foundation, a leading international supporter of research on vasculitis, is pleased to announce requests for Letters of Intent (LOI) for our 2020 research funding cycle.
$50,000 maximum for one year or $100,000 maximum for two years
International Funding Available: The VF Research Program funds research worldwide.
To improve the quality of life for patients with vasculitis, and ultimately find the cause/s and cure for vasculitis.
Letter of Intent (LOI) Submission:
For our 2020 research funding cycle, we are requiring applicants submit a Letter of Intent (LOI) outlining their proposed research project prior to submitting a grant application. The LOI should include a brief description of the project, relevance to vasculitis disease, and the applicant’s qualifications. The LOI should be maximum one-page in length, with minimum 1/2″ margins.
New deadline: The deadline for Letters of Interest submission is Saturday, June 8, 2019.
Members of the VF Research Committee will review each LOI for scientific merit, viability, and relation to the mission of the Vasculitis Foundation. All applicants will be notified whether they are invited to submit a grant application for review or not.
The deadline for invited applications will be Friday, August 2, 2019. Funding will be available in early 2020.
The VF Research Program provides one- or two-year seed grants to support pilot studies in researching:
- Etiology/Pathogenesis (could include a broad range of studies of immunity, inflammation, or vascular biology. Relevance to human vasculitis will be taken into account by the reviewers.)
- Epidemiology, including genetics
- Diagnosis, including identification of disease subtypes
- Treatment/Management, including therapeutics to treat vasculitis or prevent complications, bio markers, and psychosocial outcomes
Award Criteria: The following will be considered in making funding decisions:
- Scientific merit of the proposed project as determined by peer review.
- Importance of the area to vasculitis research.
- Availability of funds.
For more information on the LOI or application or to submit your formal LOI, please email:
Joyce A. Kullman, Executive Director
Grant applications are reviewed on the following:
1. Significance: Does this study address an important problem related to vasculitis disease? If the aims of the application are achieved, how will scientific knowledge be advanced? What will be the effect of these studies on the concepts or methods that drive this field?
2. Preliminary Evidence: Provide an account of the principal investigator’s preliminary studies or other investigator’s studies pertinent to the application information. Preliminary data can often aid reviewers in assessing the likelihood of the success of the proposed project.
3. Experimental design, methods and analysis: Are the conceptual framework design, methods, and analyses adequately developed, well-integrated, and appropriate to the aims of the project? Does the investigator acknowledge potential problem areas and consider alternative tactics?
4. Investigator(s): Is the investigator appropriately trained and well suited to carry out this work? Is the work proposed appropriate to the experience level of the principal investigator and other researchers (if any)? Is there evidence the applicant is committed to pursuing research related to vasculitis?
5. Institutional Support: Does the scientific environment in which the work will be done contribute to the probability of success? Do the proposed experiments take advantage of unique features of the scientific environment or employ useful collaborative arrangements? Is there evidence of institutional support?
6. Are human subjects involved? LOIs and grant applications may be submitted without IRB approval; if the application is selected for funding, the applicant must provide copies of approval by an institutional review board (IRB) or ethics board (EB), before funding will be released.
7. Animal Welfare. Will vertebrate animals be used in the proposed research? If yes, LOIs and grant applications may be submitted for review without approval, but if accepted for funding, statements of compliance must obtained from the American Veterinary Medicine Association and IACUC local guidelines, or equivalent documentation for non-USA countries.
8. Budget: Maximum awards will be for $50,000 for 12 months. Some awards will be available for two years at a maximum of $50,000 per year. Among grant applications with similar scores, preference will be given to applications with total budgets of $50,000 or less, to ensure that the Vasculitis Foundation can support as many investigators and as many approaches to research as possible.
1. Applicants may submit only one grant application per grant review.
2. No more than one (1) grant in any given year will be awarded to any institution or major branches of institution.
3. Applicants may hold only one grant at any given time from the Vasculitis Foundation. Investigators who are currently receiving funding (as an investigator or member of a team or from a fellowship) from the Vasculitis Foundation are not eligible to receive additional funding. The current study or fellowship must be closed and final narrative and financial reports submitted and approved by the VF Research Team before the investigator is eligible to submit a new grant application.
4. Before research can begin, grant agreements must be signed and all approvals such as IRB must be obtained.
The applications will be reviewed for responsiveness to the research objectives of the Vasculitis Foundation.
In the written review, comments on the following aspects of the grant application will be made in order to judge the likelihood that the proposed research will have a substantial impact on the pursuit of these goals. Each of these criteria will be addressed and considered in the assignment of the overall score.
The personnel category will be reviewed for appropriate staffing based on the requested percent effort. The direct costs budget request will be reviewed for consistency with the proposed methods and specific aims. Budgetary adjustments may be made by the review panel or the Vasculitis Foundation. The duration of support will be reviewed to determine if it is appropriate to ensure successful completion of the requested scope of the project.
2016 VF Research and Fellowship Report
We are pleased to provide this report on the Vasculitis Foundation’s Research and Fellowship Programs to our patients, families, physicians, researchers, and, especially, to our many donors. The VF Research program broke the $2,000,000 mark in funding in February 2016, made possible by the generous donations of our members and extended vasculitis community. Since 2002, the Vasculitis Foundation has funded 42 studies in Australia, Austria, Canada, England, Germany, Ireland, Italy, Netherlands, and the United States.
This report details our accomplishments since our Second International Vasculitis Research Consensus Conference held in Chicago, Illinois in 2012. During the conference, participants evaluated programs and explored new areas of inquiry that the Foundation could fund over the next five years.
Click here to download the report.
2012 Consensus Conference
The Vasculitis Foundation hosted the 2nd International Vasculitis Research Consensus Conference on Friday, April 20, 2012, at the Hilton Chicago, Illinois. Dr. Gary S. Hoffman, Cleveland Clinic Center for Vasculitis Care and Research, functioned as the program moderator and facilitator.
The purpose of the conference was to utilize the combined skills and experience of leading experts in vasculitis from different subspecialties and other scientific fields to evaluate the VF Research Program and explore new areas of inquiry that the Foundation should support over the next five years.
Click here to download the VF Research Consensus Conference Report 2012.
Investigator: Dan Jane-Wit, MD, PhD
Co-investigator: Caodi Fang, MS
Institution: Yale University, Department of Internal Medicine
Title: Endothelial Cell lnflammasomes in ANCA-Associated Vasculitis
Award: $25,000 for first year; $25,000 for second year
Investigators: EUVAS Council: Ingeborg Bajema, Thomas Hauser, David Jayne, Alfred Mahr and Kerstin Westman), Peter Hoglund, Lund, Sweden; Mikkel Fauschou, Copenhagen, Raashid Luqmani, Oxford, and Laura Moi
Institution: University of Cambridge, United Kingdom
Title: Long term patient follow-up of ANCA associated vasculitis, An international inception cohort study by the European Vasculitis Society
Award: $62,000 one-year
Investigator: Sonia Sharma, PhD
Co-Investigators: Rekha Dhanwani, PhD; Mohit Jain, MD, PhD
Institution: La Jolla Institute for Allergy and Immunology, Department of Cell Biology
Title: Metabolic dysregulation of pro-inflammatory responses in DADA2 vasculitis
Award: $50,000, one-year
Investigator: Mark Gorelik, MD, Co-investigator: Stephanie Davis, MS
Institution: Pediatric Rheumatology, Baylor College of Medicine
Title: Follistatin Like 1 Protein Blockade in Kawasaki Disease
Award: $25,000, one-year
Investigator: Divi Cornec, MD, PhD
Co-investigators: Ulrich Specks, MD, Pers Jacques-Olivier, PhD
Institution: Mayo Clinic, Rochester, Minnesota
Title: In Depth Characterization of PR3-specific B Cells in ANCA-associated Vasculitis
Grant: $100,000, two-years
Investigator Mary H. Foster, MD
Co-investigators: Amy Clark, PhD, Robert Tighe, MD
Institution: Nephrology, Duke University
Title: Dual immunization to model gene-environment interactions in ANCA vasculitis
Grant: One-year, $49,946
Investigator: Nataliya Milman, MD, FRCPC, MSc
Co-investigators: Peter Merkel, Annelies Boonen, Peter Tugwel, George A. Wells, Paula Patterson
Institution: Rheumatology, Ottawa Hospital Research Institute
Title: ICF Core Sets for ANCA-Associated Vasculitis
Grant: Two-year, $20,000
Analysis of Glycosylation of Proteinase 3-ANCA IgG Variable Domains, $49,500
Prof. dr. Peter Heeringa, Department of Pathology and Medical Biology, Vasculitis Expertise Center, University Medical Center, Groningen, Netherlands
Rational Treatment of Glomerulonephritis using a Novel Urine Biomarker, $49,294
Professor Mark Little, Trinity Health Kidney Centre, Nephrology, Renal Inflammation Group, St. James Hospital, Dublin, Ireland
A Randomized Multi-center Study for Isolated Skin Vasculitis (ARAMIS), $50,479
Robert Micheletti, MD, Assistant Professor, Dermatology and Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
Immune Regulation by IL-6 in Giant Cell Arteritis, $50,000
Jonathan Choy, PhD, Simon Fraser University, Burnaby, British Columbia Canada
Longitudinal Study of Morbidity and Mortality in Vasculitis Patients, $98,641 (two-year study)
Susan Jick, DSc, Professor of Epidemiology, Director Boston Collaborative Drug Surveillance Program Boston University School of Public Health, Boston, Massachusetts
Role of LAMP-2 in Tolerance to ANCA Antigens, $50,000
Renate Kain, MD, PhD, Medical University of Vienna, Vienna, Austria
The Role of micro RNA in a Novel Mouse Model of Vasculitis, $50,000
Carola G. Vinuesa, MD, MSc, PhD, John Curtin School of Medical Research The Australian National University, Canberra City, Australia
Rho-kinase Activity in Large Vessel Vasculitis, $50,000
Lindsay Lally, MD, principal investigator, Rheumatology Fellow; Robert Spiera, MD, co-investigator, Hospital for Special Surgery, New York
Microbubble Contrast-Enhanced Vascular Ultrasonography: A Novel Method of Detecting Large Vessel Vasculitis? $50,000
Kimberly P. Liang, MD, Assistant Professor of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania
Circulating microparticles as therapeutic targets of plasma exchange in antineutrophil cytoplasmic antibody (ANCA) associated vasculitis, $99,206 (two years)
Paul Brogan, FRCPCH, reader in vasculitis and honorary consultant pediatric rheumatologist, UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom
To Understand the Role of 14-3-3 In Giant Cell Arteritis (GCA), $50,000
Ritu Chakravarti, Ph.D., research associate, Department of Pathobiology, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio
Disease-specific dysregulation of miRNA in Granulomatosis with Polyangiitis (GPA/Wegener’s), $50,000
Susanne Schinke, MD, research fellow, Department of Rheumatology and Clinical Immunology, The University of Lübeck, Germany
Development of a uniform histology scoring systems for Small Vessel CNS Vasculitis in adulthood and childhood, $40,128
Susanne Benseler, MD, pediatric rheumatologist, associate professor of paediatrics, The Hospital for Sick Children, University of Toronto, Canada
Impact of Healthcare Utilization & Informal Caregiving for Primary Systemic Vasculitis: A National Perspective, $99,920
Carolyn T. Thorpe, PhD, MPH, Pharmacy and Therapeutics, University of Pittsburgh, Pennsylvania
Exome sequencing in granulomatosis with polyangiitis (GPA, Wegener’s), $50,000
Sharon Chung, MD, MAS, Division of Rheumatology, University of California, San Francisco
Investigating the molecular mechanism for IL-25-driven Act 1-dependent eosinophilic vasculitis, $50,000
Shadi Swaidani, PhD, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio
Small molecule therapeutics in Giant Cell Arteritis, $50,000
Cornelia Weyand, MD, PhD, Stanford University School of Medicine, California
Defining an animal model for the study of Wegener’s Granulomatosis, $75,000
Felipe Andrade, MD, PhD, The Johns Hopkins University, Baltimore, Maryland
Reproductive Health in Young Men and Women with Vasculitis, $49,978
Megan E. B. Clowse, MD, Rheumatology and Immunology, Duke University, Raleigh, North Carolina
Classification and Diagnostic Criteria in Primary Systemic Vasculitis, $99,738
Raashid Ahmed Luqmani, MD, Nuffield Department of Orthopaedics Rheumatology & Musculoskeletal Science Oxford, England
Identification of susceptibility genes in Takayasu’s arteritis, $50,000
Amr H. Sawalha, MD, Oklahoma City, Oklahoma
PARP-1 in CSS-associated IL-10 Promoter Polymorphisms, $50,000
Jianguo Liu, MD, PhD, Division of Immunobiology, Department of Internal Medicine, Saint Louis University School of Medicine, Saint Louis, Missouri
Vasculitic T Cells in Giant Cell Arteritis, $99,583
C.M. Weyand, MD, Emory University, Atlanta, Georgia
An Investigation of the Role of the Innate Immune Response in Kawasaki Disease, $49,980
Neil Bowles, PhD, Eccles Institute of Human Genetics, University of Utah, Salt Lake City, Utah
Investigating the role of the novel Th 17 cells in the pathogenesis of ANCA associated vasculitis and their potential for immunomodulation, $48,000
Alan Salama, MBBS, PhD, FRCP, Renal Section, Division of Medicine Imperial College London, England
Patrick Nachman, MD, University of North Carolina Kidney Center, Chapel Hill, North Carolina
Jochen Zwerina, MD, Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen, Germany
Identification and characterization of immunodominant, conformational epitopes of antineutrophil cytoplasmic antibodies, $35,000
Antje Mueller, MD, Csernok, MD, Peter Lamphrect, MD, University of Rheumatology, University Hospital Schleswig-Holstein, Campus Lubeck, Germany
Gene Expression Profile of Temporal Arteries of Giant Cell Arteritis, $35,000
Rula Hajj-Ali, MD, Cleveland Clinic, Cleveland, Ohio
Environmental Factors in the Pathogenesis of Wegener’s Granulomatosis, $35,000
Daniel Albert, MD, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
Localized Wegener’s Granulomatosis: Epidemiological, clinical and histopathological characteristics, $30,000
Peer Malte Aries, MD, and Prof. Wolfgang L. Gross, MD, Department of Rheumatology, University Hospital of Schleswig-Holstein
A Pilot Project Towards Establishment of a US/Canadian Diagnostic Registry of Children with Wegener’s Granulomatosis and Related Vasculitides, $34,900
David A. Cabral, MBBS, BC Children’s Hospital, Vancouver, British Columbia, Canada
Renal transplantation in Wegener’s granulomatosis: mortality, allograft outcomes and incidence of malignancies from the United Network for Organ Sharing database 1988-2005, $16,000
Nadine Tanenbaum, MD, Duke University, Raleigh, North Carolina
Identification of novel Wegener’s Granulomatosis Susceptibility Genes, $35,000
Katherine Siminovitch, PhD, Mount Sinai Hospital, Toronto, Ontario, Canada
Wegener’s Granulomatosis and Microscopic Polyarteritis Case Control Study in Western Montana, $7,500
Andrew Zeft, MD, Division of Immunology and Rheumatology, Department of Pediatrics, University of Utah, Salt Lake City, Utah
Development of a Measure to Assess Patients’ Adherence to Vasculitis Treatment Regimens, $35,000
Robert DeVellis, PhD, Associate Director, Arthritis Multidisciplinary Clinical Research Center, University of North Carolina, Chapel Hill, North Carolina
Analysis of NKG2D expression on CD28- T-cells and non-classical MHC-class I antigen expression on antigen-presenting cells as clues to an antigen-driven process and new targets of treatment in Wegener’s granulomatosis, $35,000
Prof. Wolfgang L. Gross, MD, and Peter Lamprecht, MD, Department of Rheumatology, University Hospital of Schleswig-Holstein, Campus Luebeck, and Rheumaklinik Bad Bramstedt, Germany
The role of shear stress in neutrophil proteinase-3 expression and its importance in vascular injury sites in Wegener’s granulomatosis, $35,000
Deborah Stearns-Kurosawa, PhD, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma
Host-microbial interactions in Wegener’s Granulomatosis: the role of ANCA and S. aureus persistence, $35,000
Robert Inman, MD, University of Toronto, Canada
Short-Term Cyclophosphamide Therapy in a Cohort of Over 200 Patients, $35,000
Gary Hoffman, MD, MS and Alexandra Villa-Forte, MD, MPH, The Cleveland Clinic, Cleveland, Ohio